[1] Coley WB.The treatment of malignant tumors by repeated inocul-ations of erysipelas with a report of ten original cases[J]. Clinical Orthopaedics & Related Research, 1991, 262: 3-11. [2] Ishida Y, Agata Y, Shibahara K, et al.Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. The EMBO Journal, 1992, 11(11): 3887-3895. [3] Chen FX, Li X, Liu JQ, et al.Tumor immunoediting and immuno-therapy[J]. Medicine and Philosophy(肿瘤免疫编辑与免疫治疗), 2007, 28(04): 59-61 [4] Yang ZY, Du XL, He XJ, et al.Thymosin α1 combined with FOLFOX4 in the treatment of advanced hepatocellular carcinoma in a complete remission case[J].CMCR(中国临床案例成果数据库), 2020, 2(1): E077-E077. [5] Zuo ZF.Thymosin α1 combined with immune checkpoint suppression in a case of advanced liver cancer[J]. CMCR(中国临床案例成果数据库), 2020, 2(1): E084-E084. [6] Graziani G, Tentori L, Navarra P.Ipilimumab: a novel immunosti-mulatory monoclonal antibody for the treatment of cancer[J]. Pharmacological Research, 2012, 65(1): 9-22. [7] Hodi FS, O'Day SJ, Mcdermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma[J]. New England Journal of Medicine, 2010, 363(8): 711-723. [8] Lynch TJ, Bondarenko I, Luft A, et al.Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study[J]. Journal of Clinical Oncology, 2012, 30(17): 2046-2054. [9] Reck M, Ciuleanu TE, Dols MC, et al.OA03. 02 Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (Chemo) vs. 4 cycles chemo as first-line (1L) treatment for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA[J]. Journal of Thoracic Oncology, 2020, 16(1): S2. [10] Kahler KC, Hauschild A.Treatment and side effect managementf CTLA-4 antibody therapy in metastatic melanoma[J]. J Dtsch Dermatol Ges, 2011, 9(4): 277-286. [11] Dillard T, Yedinak CG, Alumkal J, et al.ANTI-CTLA-4 anti-body therapy associated autoimmune hypophysitis: serious im-mune related adverse events across a spectrum of cancer subtypes[J]. Pituitary, 2010, 13: 29-38. [12] Fadel F, El Karoui K, Knebelmann B.ANTI-CTLA4 antibody-induced lupus nephritis[J]. N Engl J Med, 2009, 361(2): 211-212. [13] Li B, Vanroey M, Wang C, et al.Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2009, 15(5): 1623. [14] Kaiser J, Couzin-Frankel J.Cancer immunotherapy sweeps Nobel for medicine[J]. Science, 2018, 362(6410): 13. [15] Fan Y, Zhao J, Wang Q, et al.Camrelizumab Plus Apatinib in extensive-stage small-cell lung cancer (PASSION): a multicenter, two-stage, phase 2 trial[J]. Journal of Thoracic Oncology, 2020, 16(2): 299-309. [16] Zhuo C, Chen G, Huang Y, et al.Camrelizumab Plus Carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial[J]. The hancet 2021, 9(3): 305-314. [17] Tang B, Chi Z, Chen YB, et al. Safety, efficacy and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial[J]. Clinicalr Cancer Research, 2020, 26(16): clincancers. 3922. 2019. [18] Wang FH, Wei XL, Feng J, et al. Efficacy, safety,correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02) [J]. Journal of Clinical Oncology, 2021, 39(7): JCO. 20. 02712. [19] Shen L, Guo J, Zhang Q, et al.Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study[J]. Journal for Immunotherapy of Cancer, 2020, 8(1): e000437. [20] Wang J, Yu X, Lu S, et al.Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC)[J]. Journal of Clinical Oncology, 2020, 38(15_suppl): 9554-9554. [21] Huang X, Yang Y.Driving an improved CAR for cancer immuno-therapy[J]. Journal of Clinical Investigation, 2016, 126(8): 2795-2798. [22] Fang J, Ding N, Guo X, et al.αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib[J]. Journal for Immunotherapy of Cancer, 2021, 9(2): e001162. [23] Shi D, Shi Y, Kaseb AO, et al.Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials[J]. Clinical Cancer Research, 2020, 26(15): 3979-3989. [24] Li Y, Hermanson DL, Moriarity BS, et al.Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity[J]. Cell Stem Cell, 2018, 23(2): 181-192. [25] Guo C, Manjili MH, Subjeck JR, et al.Therapeutic cancer vaccines: past, present, and future[J]. Advances in Cancer Research, 2013, 119: 421. [26] Butterfield LH.Cancer vaccines.[J]. BMJ, 2015, 350: h988. [27] Young MD, Gooch WM 3rd, Zuckerman AJ, et al. Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination[J]. J Med Virol, 2001, 64(3): 290-298. [28] Beran J.Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients[J]. Expert Opin Biol Ther. 2008; 8(2): 235-247. [29] Charlton HHK, Vidigal J, Carrondo MJT, et al.Synthetic biology for bioengineering virus-like particle vaccines[J]. Biotechnol Bioeng, 2019, 116(4): 919-935. [30] Ogi C, Aruga A.Clinical evaluation of therapeutic cancer vaccines[J]. Human Vaccines & Immunotherapeutics, 2013, 9(5): 1049-1057. [31] Grekova SP, Aprahamian M, Daeffler L, et al.Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer[J]. Cancer Biol Ther, 2011, 12(10): 888-895. |